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13Stroke Unit, Department of InternalMedicine, St. Olavs hospital, TrondheimUniversity Hospital, Trondheim, Norway
14Centre for Prevention of Stroke andDementia, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK











Introduction:Post-stroke neurocognitive disorder (NCD) is common; prevalence varies
between studies, partially related to lack of consensus on how to identify cases. The
aimwas to compare theprevalenceof post-strokeNCDusingonly cognitive assessment
(model A), DSM-5 criteria (model B), and the Global Deterioration Scale (model C) and
to determine agreement among the threemodels.
Methods: In the Norwegian Cognitive Impairment After Stroke study, 599 patients
were assessed 3months after suffering a stroke.
Results: The prevalence of mild NCD varied from 174 (29%) in model B to 83 (14%)
in model C; prevalence of major NCD varied from 249 (42%) in model A to 68 (11%)
in model C. Cohen’s kappa and Cohen’s quadratic weighted kappa showed fair to very
good agreement among models; the poorest agreement was found for identification of
mild NCD.
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Discussion: The findings indicate a need for international harmonization to classify
post-stroke NCD.
K EYWORD S
classification, cognition, cognitive impairment, dementia, stroke
SUBJECT TERMS :
cerebrovascular disease/stroke, cognitive impairment
1 INTRODUCTION
Stroke increases the risk of cognitive impairment. However, no consen-
sus exists on how best to measure cognitive function post-stroke, and
the estimated prevalence of mild and major neurocognitive disorder
(NCD) varies according to the threshold for defined abnormalities, the
diagnostic criteria chosen, and how they are applied.1–6
The National Institute of Neurological Disorders-Canadian Stroke
Networks (NINDS-CSN) Harmonization Standards7 made a number of
recommendations regarding the choice of cognitive tests, aiming for
greater consistency across studies on vascular cognitive impairment
(VCI). Themore-recent Stroke andCognition consortium (STROKOG)2
highlighted the importance of standardizing measures and methods to
improve research quality. Widely accepted definitions of major NCD,
such as the10th versionof the International Statistical Classificationof
Diseases andRelatedHealthProblems (ICD-10)8 and the4theditionof
the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV),9
include memory impairment as an absolute feature, which is appropri-
ate for Alzheimer’s disease (AD) but not necessarily for VCI.5,10,11 In
contrast, in the 5th edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-5), any cognitive impairment—not necessarily
memory—is sufficient to meet NCD diagnostic criteria,12 an approach
thatmay bemore appropriate for impairment caused by cerebrovascu-
lar disease.5
In a systematic review of major NCD after stroke, rates ranged
from 7.4% (95% confidence interval [CI] 4.8 to 10.0) in population-
based studies of first-ever stroke excluding pre-stroke major NCD, to
53.4% (95% CI 46.9 to 59.8) in hospital-based studies of recurrent
stroke including participants with pre-stroke major NCD.4,13–15 How-
ever, heterogeneity in the case mix explained most of this variance
rather thanmethodof dementia diagnosis. The incidenceofmajorNCD
in the first year after severe major stroke is 45 times higher than the
backgroundmajorNCDrate, compared toonly three times higher after
minor stroke.14 In contrast, different methods of diagnosing mild NCD
post-stroke result inwidely varying rates of cognitive impairment, even
within a given set of diagnostic criteria in the same set of patients.1,6
Therefore, we hypothesized that, within a given patient popula-
tion, models defining mild NCD would show greater variation in mea-
sured NCD rate and lower agreement than models defining major
NCD. Diagnosing post-stroke NCD based on cognitive tests alone is
used in research.6 The recommended DSM-5 criteria11 combines a
requirement for neuropsychological performance with a requirement
for instrumental activities of daily living (I-ADL) function as part of the
diagnosis, but these requirements arenot necessarily congruent.16 The
global deterioration scale (GDS)17 is a tool assessing cognitive function
as well as the ability to perform daily life activities. In research set-
tings, it can be considered to be close to a clinical assessment. Thus,
this study’s primary aimwas to assess the prevalence of all post-stroke
NCD and, separately, mild and major NCD in the Norwegian Cognitive
Impairment After Stroke (Nor-COAST) study population using DSM-5
and to compare that with two other methods used for classification.
Further, we aimed to explore agreement among these threemethods.
2 METHODS
Nor-COAST, a multicenter prospective cohort study, recruited consec-
utive participants in five Norwegian stroke units (May 2015 to March
2017). Inclusion criteria were hospitalization with acute ischemic or
hemorrhagic stroke within 1 week after symptom onset, fluency in a
Scandinavian language, and age>18 years. The only exclusion criterion
was an expected survival of less than 3 months. Participants unable to
complete all tests due to, for example, dysphasia, poor visionorhearing,
or inability to use their dominant arm were not excluded. Participants
gave informed written consent; if unable to give consent, informed
written consentwasgivenbya family proxy. The studywasapprovedby
the Norwegian Regional Committee for Medical and Health Research
Ethics (REK) North (REC number 2015/171). The protocol for Nor-
COAST has been published previously.18
2.1 Baseline characteristics and neuropsychological
assessment
Demographic characteristics and vascular risk factors were collected
from medical records at the first assessment; stroke severity was
assessedwith theNational Institutes of Health Stroke Scale (NIHSS),19
and ischemic stroke subtype was defined according to the Trial of Org
10172 in Acute Stroke Treatment (TOAST) classification.20
Cognitive function was assessed by trained study nurses with a
30-minute neuropsychological test battery based onNINDS-CSNHar-
monization Standards7 using broadly similar neuropsychological tests
available and validated in Norwegian. The test battery comprised the
Word List Memory and Recall Test and Verbal Fluency Test Category
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(animals) from the Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) battery21,22; Verbal Fluency Test Letter (FAS)23,24;
Trail Making Tests A (TMT-A) and B (TMT-B)25; and the Montreal
Cognitive Assessment (MoCA),26 version 7.3. In addition, cognitive
function was assessed with GDS17 and the Ascertain Dementia 8-item
Informant Questionnaire (AD8).27 Activities of daily living (ADL) were
assessed with the Barthel Index (BI)28 and functional outcome with
theModified Rankin Scale (mRS).29 I-ADL was defined as the ability to
manage finances (from the relevant question in AD8) and a study ques-
tion to participants regarding their ability tomanage theirmedications.
Baseline assessments were performed during hospital stays. Three-
month follow-ups were performed at the hospitals’ outpatient clin-
ics. For participants unable to attend, assessments were performed
through telephone interviewswith theparticipants, their caregivers, or
nursing home staff with assessment of AD8, mRS, GDS, BI, information
on drugs, andwhether study participants were able to administer their
ownmedications. For telephone assessments, the TelephoneMoCA (T-
MoCA)30 was used.
2.2 Classifying cognitive status
Five of six cognitive domains cited in DSM-5 criteria were assessed;
social cognition was not measured. Complex attention was measured
by TMT-A, executive function by TMT-B and FAS, memory by Word
List Recall, language by Verbal Fluency Test Category (animals), and
perceptual-motor function by the visuospatial/executive part ofMoCA
(Figure 1).2,31
To classify cognitive status, we created three different models
(Figure 2).
Model A was based strictly on neuropsychological test scores6
meeting the cognitive requirements of the DSM-5 criteria requiring
modest cognitive decline for mild NCD and a score in the range of
−1 standard deviation (SD) to−2 SD.12 Following other studies,11,32,33
we chose −1.5 SD as the cut-off between normal cognition and mild
NCD. Participants scoring<−1.5 SD in at least one of the five cognitive
domainswere defined as having post-strokeNCD,withmildNCD scor-
ing in the range −1.5 to −2 SD andmajor NCD scoring ≤ −2 SD. Model
A is illustrated in Figure S1 in supporting information. Published inter-
national normative data from high-income Western countries compa-
rable to Norwaywere used (Table S1 in supporting information).
Model B was based on the DSM-5 criteria, which base diagnostic
workups on both neuropsychological test scores and I-ADL function.12
As in model A, participants scoring < −1.5 SD in at least one cognitive
domainweredefined ashavingpost-strokeNCD (Table S1).MajorNCD
was defined as post-stroke NCD and dependency in I-ADL; mild NCD
was defined as post-stroke NCDwithout impairments in I-ADL.34
Model C was based on GDS, a global measure of cognitive function.
The assessorswere authorized nurses carefully instructed in the use of
the scale; they used all available information from cognitive and func-
tional tests and self-/proxy reporting, making this assessment the clos-
est we could get to a clinical evaluation in our study. GDSwas originally
designed to measure cognitive decline secondary to AD17 but has also
HIGHLIGHTS
• No consensus exists on how to best measure post-stroke
neurocognitive disorder.
• In this study we compared three different methods for
defining the prevalence of post-stroke neurocognitive dis-
order.
• The prevalence of post-stroke neurocognitive disorder
varies according to themethod used to define cases.
• The poorest agreementwas found amongmodels defining
mild neurocognitive disorder
RESEARCH INCONTEXT
1. Systematic review: The authors searched the literature
using standard databases (eg, PubMed) for articles on
how to measure post-stroke neurocognitive disorder
(PSNCD). The estimated prevalence of mild and major
neurocognitive disorder (NCD) seemed to vary accord-
ing to the threshold for defined abnormalities, the diag-
nostic criteria chosen, and how they were applied. We
recognized that there were higher discrepancy and lower
agreement for definingmild thanmajor NCD.
2. Interpretation: By using three different methods for clas-
sifying NCD 3months post stroke, we demonstrated that
the prevalence of mild and major NCD varied depend-
ing on diagnostic approach. Overall agreement was bet-
ter among themethods for identificationofmajor than for
mild NCD.
3. Future directions: Before a final consensus on the defini-
tion of PSNCD can be made, more studies assessing the
reliability of different diagnostic approach are needed.
There is also aneed for studies validating the research cri-
teria for PSNCD against clinical diagnosis.
been shown to be valid for detecting vascular dementia.35,36 Scores 1–
2 indicated normal cognition; 3, mild NCD; and 4–7, major NCD.32,37
To include participants who did not complete the entire test battery
and to minimize bias from missing data, a stepwise algorithm meeting
the cognitive requirements of DSM-5 criteria was developed for use in
models A and Bwhen analyzing data (Figure 1).
Step 1 (n = 505): neuropsychological performances were based
on all completed neuropsychological tests except MoCA. Participants
included those with complete testing and those with incomplete test-
ing scoring<−1.5 SD on at least one cognitive domain.
Step 2 (n = 94): neuropsychological performance was based on
MoCA scores for participants completing MoCA only and for those
with incomplete neuropsychological testing but normal scores on com-
pleted tests.
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F IGURE 1 Stepwise algorithm for evaluation of participants’ performance on the neuropsychological test battery used inmodels A and B.
DSM-5, Diagnostic and Statistical Manual ofMental Disorders; MoCA,Montreal Cognitive Assessment; TMT-A, Trail Making Test A; TMT-B, Trail
Making Test B. The tests shown in Step 1were used to evaluate performance on the neuropsychological test battery for participants with complete
testing and those with incomplete testing scoring<−1.5 SD on at least one cognitive domain. Step 2,MoCA total score, was used to evaluate
neuropsychological performance of the participants completingMoCA only and for those with incomplete neuropsychological testing but normal
scores on completed tests
F IGURE 2 The three different analytic models for classifying neurocognitive disorder: Model A, based on neuropsychology alone;Model B,
based onDSM-5 and including I-ADL impairment; andModel C, based on the GDS. GDS, Global Deterioration Scale; I-ADL, Instrumental activities
of daily living; NCD, neurocognitive disorder; SD, standard deviation
A consensus group of experienced dementia researchers (KE, GS,
andARØ) approved this stepwise algorithmbeforedatawere analyzed.
2.3 Statistics
Z-scores normalized by mean and SD of the normative data (Table S1)
were derived from the raw scores of the neuropsychological tests
as shown in Figure 1. Lower z-scores indicate poorer outcomes. The
executive-function domain comprised two tests. If z-scores from both
tests were available, the average was taken; otherwise, the single com-
pleted test score was used.
Single items missing in MoCA and T-MoCA were imputed as des-
cribed in the supporting information. For participants starting but not
completing Trail Making Test A or B, the test result was set to 300 sec-
onds.38 Other missing data were not imputed but treated asmissing.
The proportions with normal cognition, mild, and major NCD were
calculated, with sensitivity analyses excluding pre-stroke major NCD,
defined as a pre-stroke GDS score of 4–7 and previous stroke. Agree-
ment between the models was quantified using Cohen’s kappa (𝜅), as
well as positive and negative agreement for dichotomous categories.39
For ordinal categories with more than two categories, agreement
between the models was quantified using Cohen’s quadratic weighted
kappa (𝜅w).
40 (See details in supporting information.) Data were ana-
lyzed using SPSS 25, with Extension Hub for analysis with 𝜅w.
3 RESULTS
Of the 815 participants included in the Nor-COAST study, 700 were
assessed at 3 months post-stroke. Of these, 101 had missing data; 93
hadmissing data on neuropsychological testing, due almost exclusively
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F IGURE 3 Flowchart for inclusion of participants. GDS, Global Deterioration Scale; I-ADL, Instrumental Activities of Daily Living; NIHSS,
National Institutes of Health Stroke Scale; SD, standard deviation
to severe illness; and 8 had missing data on I-ADL, resulting in a study
sample of 599 participants (mean/SD age = 72/12 years, 257 (43%)
female, mean/SD education= 12/3.8 years, mean/SDNIHSS= 3.7/4.7)
assessed at a mean/SD 3.8/0.9 months from the index stroke event
(Figure 3, Table 1).
The percentage of participants defined as having normal cognition
was highest in model C at 403 (67%) and lowest in models A and B at
267 (45%; Figure 4). The prevalence of mild NCDwas highest in model
B at 174 (29%) and lowest in model A at 83 (14%); the prevalence of
major NCDwas highest in model A at 249 (42%) and lowest in model C
at 68 (11%).
Comparing the models regarding normal cognition versus all NCD,
there was fair agreement among them (A/B and C; 𝜅 = 0.40 [95% CI
0.34 to 0.47]; Table 2). As expected, very good agreement was found
between models A and B (𝜅w = 0.85 [95% CI 0.83 to 0.88]) because
normal cognition was equally defined. However, of 332 participants
with post-stroke NCD in model A, 249 (75%) had major NCD com-
pared to 158 (48%) in model B (Figure 4). There was fair agreement
between models A and C (𝜅w = 0.38 [95% CI 0.32 to 0.44]) and mod-
erate agreement between models B and C (𝜅w = 0.52 [95% CI 0.46 to
0.58]; Table2). Thedetails underlying the counts inTable2areprovided
in Table S2 in supporting information.
Model Cwasmore restrictive in defining cognitive impairment than
model B, which was, in turn, more restrictive than model A (Figure 4).
Of 403 participants classified with normal cognition in model C, 60%
were also classifiedwith normal cognition inmodels A and B (Table S2).
The poorest agreement amongmodels was seen in the classification of
participants withmild NCD, as only 15% of the 128 classified withmild
NCD in model C were classified with mild NCD in model A and 40%
in model B. The greatest agreement was seen for the classification of
participants with major NCD, as 85% of the 68 participants classified
withmajor NCD inmodel Cwere classifiedwithmajor NCD inmodel A
and 93% inmodel B.
The exclusion of participants with pre-stroke major NCD and previ-
ous strokes resulted in a slightly higher proportion of participants hav-
ing normal cognition and a lower prevalence of major NCD, while the
prevalence ofmildNCDwas stable (Figure S2 andFigure S3 in support-
ing information).
4 DISCUSSION
In this descriptive study, we aimed to assess the prevalence of all post-
stroke NCD and subtypes mild and major NCD using three different
models. We showed that prevalence varied considerably among these
models. Overall agreement was greater among the different methods
for identification of major NCD than for mild NCD, supporting the pre-
hoc hypothesis.
To our knowledge, this is one of the few studies using DSM-5 cri-
teria (model B) to classify post-stroke NCD and comparing preva-
lence with other methods used for classifying post-stroke NCD. The
prevalence of all post-stroke NCD based on neuropsychological test-
ing (models A and B) at 55% is slightly higher than that of other recent
studies of post-stroke NCD.4,15 In these models, we found a higher
proportion of major NCD and a lower proportion of mild NCD com-
pared to the most recent review and meta-analysis,6,15 probably due
to the stepwise algorithm developed to avoid bias from missing data,
including participants unable to complete the entire neuropsycholog-
ical test battery. However, the rate of major NCD in model B at 26%
aligns with findings for hospital-based studies on first or recurrent
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TABLE 1 Baseline characteristics
Demographics N= 599
Mean age, years (SD) 72 (12)
Female sex, n (%) 257 (43)
Mean education, years (SD) 12 (3.8)
Vascular risk factors, n (%)
Hypertension, n (%) N= 599 329 (55)
Hypercholesterolemia, n (%) N= 599 304 (51)
Current cigarette smoking, n (%) N= 597 112 (19)
Diabetes mellitus, n (%) N= 599 113 (19)
Mean BMI, kg/m2 (SD) N= 567 26.1 (4.2)
Vascular disease, n (%) N= 599
Coronary heart disease, n (%) 104 (17)
Atrial fibrillation, n (%) 140 (23)
Previous stroke, n (%) 106 (18)
Previous TIA, n (%) 27 (4.5)
Stroke subtype, n (%) N= 599
Cerebral infarction 547 (91)
Cerebral hemorrhage 52 (8.7)
TOAST classification, n (%) N= 529
Large-vessel disease 56 (11)
Cardioembolic disease 123 (23)
Small-vessel disease 119 (23)
Other aetiology 15 (2.8)
Undetermined etiology 216 (41)
Thrombolysis, n (%) N= 542 143 (26)
Thrombectomy, n (%) N= 547 11 (2.0)
Pre-stroke GDS (1-7), n (%) N= 594
GDS= 1-2 536 (90)
GDS= 3 36 (6.1)
GDS= 4-7 22 (3.7)
Assessments
NIHSS (0-42) at admittance, mean
(SD)
N= 583 3.7 (4.7)
mRS (0-6) at discharge,a mean (SD) N= 597 2.1 (1.3)
Barthel Index (0-100) at
discharge,a mean (SD)
N= 597 89 (19)
Abbreviations: BMI, body mass index; GDS, Global Deterioration Scale;
mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke
Scale; SD, standard deviation; TIA, transient ischemic attack; TOAST, Trial
of Org 10172 in Acute Stroke Treatment.
aAt discharge or day 7 if length of stay extends beyond 7 days.
stroke including pre-stroke dementia in another recent review and
meta-analysis.13
In a recent paper comparing the prevalence of NCD classified by
different criteria, Sachdev et al. showed very good agreement among
DSM-5, The International Society of Vascular Behavioural and Cogni-
tive Disorders (VAS-COG), and The Vascular Impairment of Cognition
Classification Consensus Study (VICCCS) criteria, which all require
impairment in at least one cognitive domain, and lower agreement
between these criteria and DSM-IV criteria,9 requiring impairment
in memory in addition to one other cognitive domain.11 Use of the
updated DSM-512 and VAS-COG41 criteria could, therefore, lead to a
higher prevalence of all post-stroke NCD compared to studies using
DSM-IV9 or ICD-108 criteria, but for criteria demanding impairment
in the same number of cognitive domains, the prevalence of all post-
stroke NCD is probably more similar.11
Furthermore, the prevalence of mild and all post-stroke NCD will
obviously differ considerably based on the choice of cut-offs.1 The
DSM-5 criteria define modest cognitive decline as test performance
typically in the 1–2 SD range below normative mean, leaving room for
interpretation; this will significantly affect prevalence. Therefore, even
within DSM-5 criteria, the prevalence of mild and all post-stroke NCD
will vary with the use of different cut-offs.33,34,42 As we mostly used
one test per cognitive domain in the present study, we chose −1.5 SD
as the cut-off,42 which also alignswith someother studies usingDSM-5
criteria.11,33
The GDS, with similarities to clinical evaluation, was performed by
experienced nurses after explicit instruction, and it showed the lowest
prevalence of all post-strokeNCD. Theprevalence ofmajorNCDbased
on the GDS (model C) aligns with two other recent studies4,15; how-
ever, the prevalence of mild NCD is lower, possibly indicating the need
for more-comprehensive testing for classifyingmild NCD.43
The three models agreed fairly well regarding those with major
NCD but showed less agreement regarding those with mild NCD. This
supports the hypothesis that, within a given patient population, there
will be greater variation between methods used to define mild NCD
than in those defining major NCD, in line with the findings of sys-
tematic reviews on post-stroke NCD14,15 and studies of mild NCD
methodology.1,6,44 Most participants classified with major NCD by the
GDSwere also classified withmajor NCD inmodels A and B, indicating
a high specificity of this method. The discrepancy for mild and major
NCD between models A and B highlights a problem with applying the
DSM-5 criteria, as the criteria have requirements for both neuropsy-
chological performance and for I-ADL todecide on the severity ofNCD.
This could be interpreted differently across different studies and affect
prevalence and agreement.
The advantage of classifying NCD using neuropsychological tests
alone (model A) is the avoidance of the ceiling effect of commonly
used I-ADL scales that could possibly underestimate the prevalence
of major NCD, as subtle changes are difficult to detect.45 In contrast,
using neuropsychological tests alone may also result in overestimat-
ing the prevalence of major NCD.16 In model B, in line with the DSM-
5 criteria, I-ADL impairment was mandatory for major NCD, which
resulted in a shift from major to mild NCD compared to model A and
moved the prevalence of mild and major NCD closer to the findings
of other studies.13,15 The I-ADL measures we used were defined only
by ability to manage one’s medications and finances; more extensive I-
ADL measures may have given different results as I-ADL impairment
was probably underestimated. In contrast, I-ADL impairments may
also be caused by physical rather than cognitive impairment; there-
fore, I-ADL measures constructed and validated for stroke survivors
should be used.31 However, most participants in the present study had
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F IGURE 4 Proportion of participants with normal cognition, mild, andmajor NCD threemonths post-stroke, N= 599. NCD=Neurocognitive
disorder. *Model A: normal cognition defined as score≥−1.5 SD for all cognitive domains; mild NCD defined as score in the range of−1.5 to−2 SD
for at least one cognitive domain; andmajor NCD defined as a score≤−2 SD for at least one cognitive domain. †Model B: normal cognition defined
as score≥−1.5 SD for all cognitive domains; NCD defined as score<−1.5 SD for at least one cognitive domain; major NCD defined as having
post-stroke NCDwith dependency in instrumental activities of daily living (I-ADL), defined as the need for assistance inmanaging one’s finances
and/or medications. Mild NCDwas post-stroke NCDwithout impairments in I-ADL. ‡Model C: evaluation based on Global Deterioration Scale
(GDS); normal cognition defined as a GDS score of 1–2; mild NCD defined as a GDS score of 3; andmajor NCD defined as a GDS score of 4–7
experienced milder strokes, so this may have been less important.
Based on prevalence of all post-stroke NCD, mild, and major NCD in
other studies, our findings support the classification of post-stroke
NCD based on both neuropsychological tests and I-ADLmeasures.
Major strengths of the present study were its multicenter design,
providing a fairly representative stroke population, and the use of rec-
ommended robust tests for stroke patients.7 Another strength is the
stepwise algorithmdeveloped to avoid bias frommissing data, allowing
inclusion of participants unable to complete the entire test battery.
The study also has several limitations. The lack of a stroke-free con-
trol group made it difficult to evaluate the extent to which the mea-
sured post-stroke NCD was greater than expected in the background
population.14 Additionally, cognitive domains were assessed using a
limited number of neuropsychological tests; only one test in most
domains that may have overestimated the impairments,34 but lengthy
batteries are often poorly tolerated by frail older patients and may
result in selection bias underestimating the impairments.46 In line with
DSM-5 criteria, we included measures of I-ADL, but this was defined
only by ability to manage one’s medications and finances, probably
underestimating the I-ADL impairments.
5 CONCLUSION
In this study, the prevalence of mild and major NCD varied depending
on diagnostic approach. Overall agreement was better between the
different methods for identification of major NCD than for mild NCD,
supporting our hypothesis. The present study shows that there is need
for more research with focus on validating research diagnosis against
clinical diagnosis of post-stroke NCD. Data collected for research are
more limited than the information used in clinical diagnostic work-
up on patients’ cognitive status, on the other hand making clinical
diagnosis in large research studies not feasible. Issues remain in the
interpretation and application of methods for classifying post-stroke
NCD. The DSM-5 criteria are not specific enough regarding which
cut-off values for impairments in cognitive tests should be applied and
to decide on the severity ofNCD. Furthermore, I-ADLmeasures associ-
atedwith cognitive impairment in a strokepopulationneed tobebetter
defined.
We recommend using the combination of neuropsychological tests
and a valid measure of I-ADLs when classifying post-stroke NCD.
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